🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

KYNB KYNB

Company Profile ↓
$6.99
+0.87% 1Y
P/E0.15
52W High$12.43
52W Low$6.46
EPS (TTM)$45.37

Company Overview

KYNB (KYNB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Reasonable Valuation

Trades at an undemanding P/E of 0.1.

Recent Developments

  • Dec 2025 Revenue of $6.44M (-78.3% YoY); net profit $183.45M.
  • Trailing 12 Months Year-on-year growth — revenue -78.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR -20.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-20.57%
1 Year:-78.26%

Stock Price Performance

1 Year:+0.87%
6 Months:-17.76%
3 Months:-1.55%
1 Month:-7.29%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 9% of range
$6.46 $12.43
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)48.01 · Neutral
Price Performance
1M-7.29%
3M-1.55%
6M-17.76%
1Y+0.87%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -20.6% CAGR over 5 years.
  • Trading 43.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
0.15
Industry PE
-
Forward P/E est.
0.30
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-20.57%
Profit 5Y
-
Revenue (YoY)
-78.26%
Earnings (YoY)
-

Profitability & Returns

ROCE
-50.80%
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-3.76
EPS (TTM)
$45.37

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$109.63M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.02%
Chg in Prom Hold
-
FII / Inst Holding
25.57%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$6.44M
EBITDA
-
Free Cash Flow
$-4.81M
Operating Cash Flow
$-4.77M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ----------30.27M40.55M31.93M43.95M29.03M23.86M191.57M33.17M24.40M42.89M44.03M38.43M24.36M155.97M60.83M29.81M15.73M36.16M44.32M40.13M25.36M998.00K123.00K2.74M1.35M1.08M3.74M
Operating Income -14.21M49.17M-37.09M-44.72M59.31M-43.77M-26.79M26.51M-22.10M-28.82M-30.14M-22.74M-40.60M-23.24M-42.77M-48.84M112.82M-52.85M-81.07M-85.14M32.33M-70.43M-133.84M50.97M-62.99M-78.22M-93.66M-76.09M-88.05M-63.48M-49.18M-46.41M-47.69M-14.92M-12.05M-5.41M-13.82M
Net Income -16.24M46.83M-39.53M-46.37M57.05M-45.10M-27.84M24.32M-24.15M-30.61M-31.91M-24.46M-41.40M-23.42M-42.56M-45.41M116.00M-49.44M-78.35M-85.31M33.00M-71.75M-133.99M49.80M-63.20M-72.62M-91.65M-76.70M-87.68M-63.62M-32.93M-15.54M-17.08M4.64M-7.60M200.64M-15.20M
Diluted EPS -0.58--0.83--0.35---0.48---0.28-0.50-1.26-0.57--0.950.35--1.450.54-0.68-0.78-0.98-0.81-0.90-0.65-0.33-3.89-4.251.15-1.8849.61-3.76
R&D Expense 25.65M33.27M40.62M50.54M51.55M52.07M43.65M52.39M40.56M46.73M46.98M50.34M56.97M52.14M56.44M50.50M52.01M49.96M54.90M61.41M58.48M74.68M122.57M75.88M89.02M70.96M75.18M74.49M95.48M61.19M36.49M32.36M19.97M9.18M5.87M1.21M7.57M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 102.17M137.60M180.83M183.19M131.00M212.96M256.58M176.32M235.31M140.73M46.80M29.62M6.44M
Operating Income -7.95M-50.10M-77.62M-50.04M-117.28M-86.69M-89.31M-191.88M-288.53M-301.02M-322.72M-150.42M-45.90M
Net Income -14.94M-59.50M-85.78M-58.07M-120.88M-86.42M-76.97M-189.29M-290.02M-293.65M-284.23M-47.58M183.45M
Diluted EPS --------2.11-3.14-3.14-2.92-11.8945.37
R&D Expense 85.71M150.79M214.09M187.21M196.52M235.84M209.26M252.92M387.04M296.79M266.47M95.69M23.52M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Aug 2025Dec 2025
Total Assets --483.53M470.57M469.55M898.65M880.60M857.40M826.84M773.82M610.09M423.53M214.53M-119.59M
Total Equity -46.25M-60.83M221.41M177.55M155.84M528.47M509.20M516.13M422.18M209.15M-21.45M-204.17M-225.60M--30.04M
Cash & Equivalents 38.87M76.33M165.46M153.32M173.78M673.66M89.26M126.27M678.39M171.22M155.70M81.55M50.48M-47.87M
Long Term Debt -------------75.00M-
Total Liabilities --242.85M273.75M294.44M350.91M352.13M321.99M385.39M544.71M611.57M585.73M398.16M-115.12M
Current Liabilities --62.75M67.18M65.12M85.96M89.03M102.75M163.19M225.50M273.56M217.67M133.31M-29.24M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ---7.11M-66.51M-76.14M-78.70M81.60M-82.23M-145.93M-315.02M-138.00M-4.77M
Investing Cash Flow ---6.62M69.87M-522.12M120.02M452.49M-426.97M89.12M153.66M125.99M35.42M
Financing Cash Flow ---6.74M496.47M13.88M-4.30M13.34M-563.00K46.78M122.75M-255.00K-86.03M
Capital Expenditure -6.81M-8.12M-1.98M-1.25M-8.50M-8.02M-5.76M-3.99M-5.19M-3.74M-2.52M-266.00K-38.00K
Free Cash Flow ---5.86M-75.01M-84.16M-84.47M77.61M-87.42M-149.67M-317.54M-138.26M-4.81M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -7.8%-36.4%-42.9%-27.3%-89.5%-40.7%-34.8%-108.8%-122.6%-213.9%-689.5%-507.8%-712.7%
Net Margin % -14.6%-43.2%-47.4%-31.7%-92.3%-40.6%-30.0%-107.4%-123.3%-208.7%-607.3%-160.6%2,848.6%
ROE % 24.6%-26.9%-48.3%-37.3%-22.9%-17.0%-14.9%-44.8%-138.7%1,369.2%139.2%21.1%-610.7%
ROCE % --11.9%-19.2%-12.4%-14.4%-11.0%-11.8%-28.9%-52.6%-89.5%-156.8%-185.2%-50.8%

Shareholding Pattern

Insiders
2.02%
Institutions
25.57%
Public Float
26.10%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KYNB

Yahoo Finance Mon, 03 Aug 2026

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo Finance hu, 30 Jul 2026

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance hu, 23 Jul 2026

NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of +56.67% and +5.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance hu, 11 Jun 2026

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placeboSimilar rates of T…

Yahoo Finance ue, 12 May 2026

Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...

Kyntra Bio Inc (KYNB) reports increased revenue and improved cost management, while advancing key clinical trials and maintaining a strong cash position.

Yahoo Finance Mon, 11 May 2026

Kyntra Bio (KYNB) Q1 2026 Earnings Transcript

Gaia Vasiliver-Shamis: Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. Joining me on today’s call are Thane Wettig, chief executive officer, Davi…

KYNB — Frequently Asked Questions

What is the current share price of KYNB?

As of 2026-08-05 17:25 PDT, KYNB trades at $6.99 on NASDAQ/NYSE. Its 52-week range is $6.46 to $12.43.

What is the P/E ratio of KYNB?

KYNB trades at a trailing price-to-earnings (P/E) ratio of 0.15.

Is KYNB a good stock to buy?

This page provides a data-driven analysis of KYNB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space